Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(33)
•••
Comment by toinv261on Mar 08, 2015 1:38pm
253 Views
Post# 23501271

RE:RE:RE:RE:Anacetrapib - another CETP still killing people?

RE:RE:RE:RE:Anacetrapib - another CETP still killing people?Hi Priceless2.

I'm not a science poster. I'm mathematics and statistics guy so yes we need POVs from the science folks.

Just a couple of points. rvx-208 + Crestor achieved RRR of 77% at day 210 in the combined ASSURE/SUSTAIN trial AND BETonMACE only needs to achieve 30% RRR to be clinically significant. So that should improve odds of success very significantly IMHO.

Add to this that RVX now has the results of the Emerald Logic FACET predictive modelling analysis of the combined ASSURE/SUSTAIN data (along with all of the other information from 15 years of testing that they would have put into this modelling) and this should put them into a position of understanding the odds much better as well as many other benefits as pointed out by fouremm.

I've been having problems with Stockhouse today.
So GLTA
Cheers
Toinv
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities